Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

On behalf of our sponsors at Tonum Health, we're leaning about the millions of Americans using weight loss medications like Ozempic and Wegovy. There's now a growing conversation around what happens ...

In June, Novo ended a partnership with Hims & Hers that provided access to Wegovy through the pharma's Novocare Pharmacy because Hims & Hers was trying to skirt legal restrictions on compounding ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC antitrust review and regulatory scrutiny.

The FDA-approved medications for weight loss and diabetes remain a life-changing therapy in many countries, and for some ...

Ozempic, Mounjaro and Wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid ...

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as next week.

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...